ANDREW TRAN: Open Payments
NPI 1770936577 · SALINAS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$948 in 49 payments from 11 companies in 2025. Trend: 2023 $56 · 2024 $872 · 2025 $948
Food & beverage: $948
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $199 |
| Neurocrine BioSciences, Inc. | 7 | $193 |
| Alkermes, Inc. | 9 | $175 |
| Axsome Therapeutics, Inc. | 4 | $120 |
| Tris Pharma Inc | 5 | $107 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $43 |
| E.R. Squibb & Sons, L.L.C. | 1 | $29 |
| PFIZER INC. | 1 | $25 |
| Teva Pharmaceuticals USA, Inc. | 1 | $23 |
| Janssen Pharmaceuticals, Inc | 1 | $19 |
Products named: VRAYLAR, INGREZZA, ARISTADA, Auvelity, Dyanavel XR, Onyda XR, CAPLYTA, COBENFY.
Industry payments across CA — which companies pay providers there.
